ResearchHub Logo
Currency
Display format
RSCUSD

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Authors
Ying ChengDavid SpigelMartijn Dorp
Journal
New England Journal of Medicine
Published
September 13, 2024

Abstract

Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent platinum-based chemoradiotherapy.

Supporters

Support the authors with ResearchCoin

Topics

DOI

10.1056/nejmoa2404873

License

Unknown License
Durvalumab after Chemoradiotherapy in Limited-Stage Small... | ResearchHub